In a study examining magic mushrooms in Canada, nearly 80% of participants expressed their view that psilocybin should be made medically available to patients experiencing distress. Moreover, about two-thirds of the Canadian respondents in the same study concurred that psilocybin should be legally attainable for those who require it.
Besides advocating for easier access to the substance, a substantial 84.8 percent of participants felt that the public health system should bear the expense of such therapies. A majority of Canadians view psilocybin as a credible alternative, especially for treating end-of-life distress.
[toc]
Key Findings:
- Residents of Québec, Ontario, Alberta, and British Columbia view psilocybin as a legitimate medical option for addressing end-of-life existential distress.
- Magic mushrooms are perceived as safe for the treatment of existential distress.
- Participants in two double-blind trials noted immediate and lasting benefits, with effects persisting for six months or even more.
Understanding Existential Distress
Existential distress, similar to existential suffering, spiritual distress, and demoralization, arises when individuals grapple with their mortality. Patients may undergo feelings of helplessness, isolation, anxiety, and a loss of purpose. This form of distress primarily impacts patients with life-threatening diseases, potentially leading to thoughts of hastening death or contemplating suicide.
Usually, individuals facing terminal illnesses or significant life changes are the ones who frequently experience this kind of distress. It severely impacts their mental health and overall quality of life.
Existential therapy aims to address issues such as anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. It may necessitate multiple sessions and might not be effective for everyone.
The unpredictability of the effectiveness of such therapy is a main reason why many individuals seek alternative treatments.
Health Canada’s Stance on Psilocybin as a Therapeutic Option
Over the last two decades, preliminary clinical trials have highlighted the potential advantages of psychedelic substances in managing complex mental disorders. Specifically, Psilocybin has demonstrated a rapid and lasting relief of existential distress in patients nearing the end of their lives.
Recognizing the possible effectiveness of hallucinogenic mushrooms, particularly when conventional treatments are ineffective, Health Canada updated the Special Access Program in 2022. This revision permits healthcare professionals to procure controlled substances for their patients.
Canadian Support for Access to Psilocybin
A study showcased in the Palliative Care Journal evaluates societal views on psilocybin-assisted therapy for end-of-life care. The study’s data includes:
| Methodology | Participation from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% of whom had previously used psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% view psilocybin-assisted therapy as a legitimate medical option for treating end-of-life existential distress. 63.3% believe psilocybin should be integrated into medical treatment. 84.8% endorse the delivery of this therapy by the public health system. 44.2% believe healthcare professionals should administer the substance without Health Canada’s supervision. |
These outcomes align with surveys from Canada, England, and Australia. The researchers highlighted the uniqueness of their study as it focuses on the use of psychoactive substances to manage existential distress in end-of-life situations.
Reasons for Canadian Approval of Psilocybin Use
An increasing number of Canadians are endorsing the use of psilocybin for treatment, primarily due to results from esteemed research institutions. Another influential factor is the perceived safety of psilocybin mushrooms in relieving existential distress. Participants across various studies have not reported severe adverse health effects, such as multi-organ failure.
| Study | Method | Results |
| Johns Hopkins Study | 51 patients were administered a high dose of psilocybin and a low dose as an active placebo control | Immediate and prolonged The effectiveness of the therapy is largely attributed to mystical experiences that are characterized by a profound emotional understanding and a sense of unity. These experiences can provide benefits for up to six months or longer. |
| New York University Trial | 29 patients were randomly selected to receive either psilocybin or the active placebo, niacin. | The results of this study were consistent with those of the Johns Hopkins study. Participants who received psilocybin reported psychological relief, as well as an improved outlook on life and death. |
| BMC Palliative Care | The study was conducted with nineteen participants consisting of 7 doctors, 4 practicing nurses, 4 chaplains, 3 social workers, and a psychologist. The objective of the study was to gain insight into how professionals in palliative care perceive existential distress and their opinions on psychedelic therapy as a treatment option. | The palliative care professionals interviewed suggested that psychedelic-assisted therapy (PAT) could potentially alleviate existential distress. |
Patient Experiences
Scientific studies are not the only evidence supporting the effectiveness of psilocybin. There are numerous patient narratives that emphasize its ability to improve mental health and overall quality of life.
The Journey of Yokoi
Mio Yokoi, a patient suffering from terminal stage 4 pancreatic cancer, shares a transformative experience during her assisted therapy. She visualizes herself on a raft surrounded by nature and fantastical creatures. This vision imbues her with a profound recognition of the universe’s interconnectedness and support, providing her with immense peace and affirmation.
Despite accessing conventional mental health support, Yokoi continued to struggle with severe anxiety and distress following her diagnosis. Psilocybin therapy allowed her to reconnect with her body and provided a tangible sense of love and support. This significantly improved her mental and emotional health.
The Story of Chrissy
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer that had metastasized to her lungs. She was working full-time as an administrative supervisor in healthcare during the study and identified as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy experienced significant decreases in her levels of anxiety, depression, fear of death, hopelessness, and demoralization following her therapy. When asked about any changes in her religious or spiritual beliefs since her therapy session, she responded that the experiences had brought a new sense of reality and meaning to her beliefs.
The Experience of Brenda
In her therapeutic sessions, Brenda had two near-death experiences. After these occurrences, she no longer feared death and began to see it as a natural part of life’s cycle. She credited the study for initiating her healing journey from childhood trauma. Her data reflected this profound change.
Decreased anxiety and fear of death, along with increased spirituality, were observed.
Availability of Magic Mushroom Products in Canada
At present, there may be limitations on the availability of psilocybin capsules and other products designed for managing existential distress or other mental health disorders. Nonetheless, reliable online dispensaries can be a valuable resource for these products when needed.
| Characteristic | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and certain South American regions. | Discovered in Cambodia, near the Angkor Wat Temple. | Linked to Penis Envy mushrooms, which became popular in the 1970s. |
| Potency | Moderately potent; suitable for beginners. | Moderately potent as well; perfect for novices. | Extremely potent; advised for individuals with intermediate to advanced experience. |
| Effects | Triggers a mental buzz, slight disorientation, color perception enhancement, euphoria, spiritual experiences, increased creativity, and improved focus. | Induces an energizing and lasting high, minor visual alterations, enhanced creativity, euphoria, a smooth physical high, fractal images, and feelings of joy. | Provokes profound shamanic experiences, vision quests, intense mystical experiences, increased creativity, focus, social awareness, and mood upliftment. |
Mitigate End-of-life Distress with Psilocybin Products
Existential or end-of-life distress can impose a significant burden on many patients nearing the end of their lives. Traditional treatments may sometimes fail to address this distress, leading to growing support in Canada for easier access to magic mushrooms within the public healthcare system. This rising public interest could
We advocate for the consideration of magic mushrooms as a legitimate treatment option by regulatory bodies. Obtain your psychedelics and mushroom delivery from Micro Zoomiez Canada.
Frequently Asked Questions
What should patients expect from Psilocybin-Assisted Therapy?
The experiences of patients undergoing Psychedelic-assisted therapy (PAT) differ significantly. To ensure a positive outcome, it is vital to follow certain steps and prepare appropriately. A thorough screening and mental readiness are needed before taking the substance.
- Session Preparation: A comprehensive evaluation of the patient is conducted. The therapist discusses the patient’s goals and expectations to set intentions for the session. The therapist also explains the potential impact of the process and what the patient can expect during the session.
- The Session: A controlled dose of the substance is given to the patients during the session, which takes place in a serene, distraction-free environment to promote relaxation and introspection. During this time, the therapist offers ongoing support and guidance.
- Post-Session Integration Therapy: This therapy helps the patient comprehend and process their experiences. Additional sessions provide ongoing support and counselling to reinforce the insights and changes realized during the therapy.
How does psilocybin influence the brains of distressed patients?
Psilocybin interacts with the brain by binding to serotonin receptors, specifically the 5-HT2A receptor. This interaction can cause alterations in perception, mood, and cognition, leading to substantial shifts in consciousness, emotional breakthroughs, and new perspectives.
Is psilocybin therapy available to everyone?
Psilocybin therapy is not appropriate for everyone. Patients with specific mental health conditions or existential distress are thoroughly screened to exclude those with a history of psychosis.
Related Articles:
